Diagnostic Histopathology
Volume 14, Issue 8 , Pages 335-351 , August 2008

Immunohistochemical markers as a diagnostic aid in ovarian pathology

References 

  1. McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology. 2002;40:309–326
  2. Baker PM, Oliva E. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol. 2005;24:39–55
  3. McCluggage WG. Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol. 2000;53:327–334
  4. Deavers MT, Malpica A, Silva EG. Immunohistochemistry in gynecological pathology. Int J Gynecol Cancer. 2003;13:567–579
  5. Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol. 2001;20:64–78
  6. McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol. 2005;22:3–32
  7. Young RH, Scully RE. Differential diagnosis of ovarian tumors based primarily on their patterns and cell types. Semin Diagn Pathol. 2001;18:161–235
  8. Bertelsen K, Holund B, Andersen E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer. 1993;3:72–79
  9. Brugghe J, Baak JP, Wiltshaw E, Fisher C. Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment. Int J Gynecol Cancer. 1995;5:262–268
  10. Baak JP, Langley FA, Talerman A, Delemarre JF. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol. 1986;8:354–357
  11. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152–163
  12. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms’ tumor gene (WTI) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158–163
  13. Al Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109–115
  14. McCluggage WG. WTI is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol. 2004;3:97–99
  15. Hashi A, Yuminamochi T, Murata S, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium and peritoneum. Int J Gynecol Pathol. 2003;22:374–377
  16. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol. 2003;27:1434–1441
  17. O’Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology. 2007;50:773–779
  18. Chiesa-Vottero AG, Malpica A, Deaver MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328–333
  19. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1β in ovarian and endometrial clear-cell adenocarcinomas and non-neoplastic endometrium. Hum Pathol. 2007;38:1074–1080
  20. Kato N, Sabou S, Motoyama T. Expression of hepatocyte nuclear factor-1 beta (HNF-1 beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19:83–89
  21. Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–1518
  22. O’Neill CJ, Deavers MT, Malpica A. An immunohistochemical comparison between low-grade and high-grade serous carcinomas. Significantly higher expression of p53, MIB1, bcl2, HER-2/neu, and C-KIT in high grade neoplasms. Am J Surg Pathol. 2005;29:1034–1041
  23. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: a morphologic study with emphasis on differential diagnosis. Am J Surg Pathol. 2004;8:453–463
  24. Liao XY, Xue WC, Shen DH, et al. p63 expression in ovarian tumours: a marker for Brenner tumours but not transitional cell carcinomas. Histopathology. 2007;51:477–483
  25. Ordonez NG. Transitional cell carcinomas of the ovary and bladder are phenotypically different. Histopathology. 2000;36:433–438
  26. Ogawa K, Johansson SL, Cohen SM. Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues and benign and neoplastic lesions of the female genital tract. Am J Pathol. 1999;155:1047–1050
  27. Riedel I, Czernobilsky B, Lifschitz-Mercer B, et al. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers including cytokeratins and uroplakins. Virchows Arch. 2001;435:181–191
  28. Soslow RA, Rouse RV, Hendrickson MR, et al. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis. Int J Gynecol Pathol. 1996;15:257–265
  29. Pitman MB, Triratanachat S, Young RH, et al. Hepatocyte paraffin 1 antibody does not distinguish primary ovarian tumors with hepatoid differentiation from metastatic hepatocellular carcinoma. Int J Gynecol Pathol. 2004;23:58–64
  30. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol. 2002;55:27–31
  31. Miller K, Price JH, Dobbs SP, McClelland RH, Kennedy J, McCluggage WG. An immunohistochemical analysis of post-chemotherapy ovarian carcinomas. J Clin Pathol. 2008;61:652–657
  32. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41–44
  33. Hart W. Diagnostic challenge of secondary (metastatic) ovarian simulating primary endometrioid and mucinous neoplasms. Pathol Int. 2004;55:231–243
  34. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology. 2005;47:231–247
  35. Lee KR, Young RH. The distinction between primary and secondary mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281–292
  36. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998;29:491–497
  37. Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol. 1996;9:426–429
  38. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4 and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21:391–400
  39. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002;33:1078–1085
  40. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303–310
  41. Groisman GM, Meir A, Sabo E. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int J Gynecol Pathol. 2004;23:52–57
  42. Tornillo L, Moch H, Diener PA, et al. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J Clin Pathol. 2004;37:641–643
  43. Raspollini MR, Amunni G, Villanucci A, et al. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases. Appl Immunohistochem Mol Morphol. 2004;12:127–131
  44. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol. 2005;18:19–25
  45. Lewis MR, Deavers MT, Silva EG, Malpica A. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol. 2006;30:177–184
  46. Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol. 2005;24:4–25
  47. Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol. 2006;25:83–89
  48. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol. 2006;19:97–105
  49. Vang R, Gown AM, Zhao C, et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol. 2007;31:854–869
  50. Chou YY, Jeng YM, Kao HL, et al. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology. 2003;43:151–156
  51. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 2004;24:67–72
  52. Tejper S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615–6620
  53. Young RH, Hart WR. Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and secretory endometrioid carcinoma: a clinicopathologic and immunohistochemical study of five cases. Am J Surg Pathol. 1998;22:805–815
  54. Young RH, Hart WR. Metastasis from carcinomas of the pancreas simulating primary mucinous tumors of the ovary. A report of seven cases. Am J Surg Pathol. 1989;13:748–756
  55. Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol. 2006;30:277–299
  56. Lerwill MF, Young RH. Ovarian metastasis of intestinal-type gastric carcinoma: a clinicopathologic study of 4 cases with contrasting features to those of Krukenberg tumor. Am J Surg Pathol. 2006;30:1382–1388
  57. Hristov AC, Young RH, Vang R, et al. Ovarian metastasis of appendiceal tumors with goblet cell carcinoidlike and signet ring cell patterns: a report of 30 cases. Am J Surg Pathol. 2007;31:1502–1511
  58. Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems and proposed classification. Adv Anat Pathol. 2005;12:291–311
  59. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19:1390–1408
  60. Guerrieri C, Franlund B, Boeryd B. Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix. Mod Pathol. 1995;8:573–576
  61. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol. 1997;16:1–9
  62. Monteaguda C, Merino MJ, La Porte N, et al. Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary. Hum Pathol. 1991;22:368–372
  63. Sasaki E, Tsunoda N, Hatranaka Y, et al. Breast-specific expression of MGB1 mammaglobin: an examination of 480 tumors from various organs and clinicopathologic analysis of MGB-1 positive breast cancers. Mod Pathol. 2007;20:208–214
  64. Onuma K, Dabbs DJ, Bhargava R. Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium – a potential clinical utility in gynecologic pathology. Int J Gynecol Pathol. 2008;27:418–425
  65. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125 and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005;29:1482–1489
  66. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005;29:281–294
  67. Vang R, Gown AM, Farinola M, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007;31:653–663
  68. Irving JA, Young RH. Lung carcinoma metastatic to the ovary. A clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis. Am J Surg Pathol. 2005;29:997–1006
  69. Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2007;31:1759–1763
  70. Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 (TTF-1) expression in ovarian epithelial neoplasms. Mod Pathol. 2008;21:485–490
  71. Cameron RI, Ashe P, O’Rourke DM, et al. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2003;22:272–276
  72. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary adenocarcinoma of the ovary and peritoneum. Histopathology. 2002;20:237–244
  73. Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrioid and ovarian carcinoma. A prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol. 2001;83:355–362
  74. Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol. 1985;16:28–34
  75. Brinkmann D, Ryan A, Ayhan A, et al. A molecular genetic and statistical approach for the diagnosis of dual-site cancers. J Natl Cancer Inst. 2004;96:1441–1446
  76. Matias-Guiu X, Lagarda H, Catasus L, et al. Clonality analysis in synchronous or metachronous tumors of the female genital tract. Int J Gynecol Pathol. 2002;21:205–211
  77. Goldstein NS, Uzieblo A. WTI immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;17:541–545
  78. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004;28:160–167
  79. Gupta D, Deavers MT, Silva EG, et al. Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases. Am J Surg Pathol. 2004;28:771–780
  80. McCluggage WG, Bissonette JP, Young RH. Primary malignant melanoma of the ovary: a report of 9 definite or probable cases with emphasis on their morphologic diversity and mimicry of other primary and secondary ovarian neoplasms. Int J Gynecol Pathol. 2006;5:321–329
  81. Stewart CJ, Nandini CL, Richmond JA. Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol. 2000;53:206–211
  82. Yao DX, Soslow RA, Hedvat CV, et al. Melan-A (A103) and inhibin expression in ovarian neoplasms. Appl Immunohistochem Mol Morphol. 2003;11:244–249
  83. Deavers MT, Malpica A, Ordonez NG, et al. Ovarian steroid cell tumors: an immunohistochemical study including a comparison of calretinin with inhibin. Int J Gynecol Pathol. 2003;22:162–167
  84. Anderson AE, Yang X, Yang RH. Epithelioid angiomyolipoma of the ovary: a case report and literature review. Int J Gynecol Pathol. 2002;21:69–73
  85. Cathro HP, Stoler MH. The utility of calretinin, inhibin and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005;36:195–201
  86. McCluggage WG, Maxwell P. Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathology. 2001;38:403–408
  87. Cao QJ, Jones JG, Li M. Expression of calretinin in human ovary, testis and ovarian sex cord-stromal tumors. Int J Gynecol Pathol. 2001;20:346–352
  88. McCluggage WG, Maxwell P. Adenocarcinomas of various sites may exhibit immunoreactivity with anti-inhibin antibodies. Histopathology. 1999;35:216–220
  89. McCluggage WG, Maxwell P, Sloan JM. Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin. Hum Pathol. 1997;28:1034–1038
  90. Stewart CJ, Jeffers MD, Kennedy A. Diagnostic value of inhibin immunoreactivity in ovarian gonadal stromal tumours and their histological mimics. Histopathology. 1997;31:67–74
  91. Costa MJ, Ames PF, Walls J, et al. Inhibin immunohistochemistry applied to ovarian neoplasms: a novel, effective, diagnostic tool. Hum Pathol. 1997;28:1247–1254
  92. Kommoss F, Oliva E, Bhan AK, et al. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod Pathol. 1998;11:656–664
  93. Riopel MA, Perlman EJ, Seidman JD, et al. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcaemic small cell carcinomas. Int J Gynecol Pathol. 1998;17:46–53
  94. Rishi M, Howard LN, Bratthauer GL, et al. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 1997;21:583–589
  95. Pelkey TJ, Frierson HF, Mills SE, et al. The diagnostic utility of inhibin staining in ovarian neoplasms. Int J Gynecol Pathol. 1998;17:97–105
  96. Guerrieri C, Franlund B, Malmstrom H, et al. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: a study using inhibin and cytokeratin 7. Int J Gynecol Pathol. 1998;17:266–271
  97. Deavers MT, Malpica A, Liu J, et al. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol. 2003;16:584–590
  98. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol. 2002;26:1477–1483
  99. Shah VI, Freites ON, Maxwell P, et al. Inhibin is more specific than calretinin as an immunohistochemical marker for differentiating sarcomatoid granulosa cell tumour of the ovary from other spindle cell neoplasms. J Clin Pathol. 2003;56:221–224
  100. Flemming P, Wellmann A, Maschek H, et al. Monoclonal antibodies against inhibin represent key markers of adult granulosa cell tumors of the ovary even in their metastases. A report of three cases with late metastasis, being previously misinterpreted as haemangiopericytoma. Am J Surg Pathol. 1995;19:927–933
  101. Loo KT, Leung AK, Chan JK. Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody. Histopathology. 1995;27:388–390
  102. Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol. 1998;29:840–845
  103. Oliva E, Garcia-Miralles N, Vu Q, et al. CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases. Int J Gynecol Pathol. 2007;26:359–367
  104. Vang R, Herrmann ME, Tavassoli FA. Comparative immunohistochemical analysis of granulosa and Sertoli components in ovarian sex cord-stromal tumors with mixed differentiation: potential implications for derivation of Sertoli differentiation in ovarian tumors. Int J Gynecol Pathol. 2004;23:151–161
  105. Farinola MA, Gown AM, Judson K, et al. Estrogen receptor α and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol. 2007;26:375–382
  106. Bamberger AM, Ivell R, Balvers M, et al. Relaxin-like factor (RLF): a new specific marker for Leydig cells in the ovary. Int J Gynecol Pathol. 1999;18:163–168
  107. Zhao C, Bratthauer GL, Barner R, et al. Diagnostic utility of WT1 immunostaining in ovarian Sertoli cell tumor. Am J Surg Pathol. 2007;31:1378–1386
  108. McCluggage WG, McKenna M, McBride HA. CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors. Int J Gynecol Pathol. 2007;26:322–327
  109. Ohishi Y, Kaku T, Oya M, et al. CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls. Gynecol Oncol. 2007;107:30–38
  110. Kingston GT, Manek S. CD56 immunoreactivity in ovarian sex cord-stromal tumours. Histopathology. 2007;51:723–725
  111. Aguirre P, Thor AD, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors. Int J Gynecol Pathol. 1989;8:364–373
  112. McCluggage WG, Young RH. Ovarian Sertoli-Leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid Sertoli-Leydig cell tumors). Am J Surg Pathol. 2007;31:592–597
  113. Costa MJ, De Rose PB, Roth LM, et al. Immunohistochemical phenotype of ovarian granulosa cell tumors: absence of epithelial membrane antigen has diagnostic value. Hum Pathol. 1994;25:60–66
  114. McCluggage WG. Immunoreactivity of ovarian juvenile granulosa cell tumours with epithelial membrane antigen. Histopathology. 2005;46:235–236
  115. Otis CN, Powell JL, Barbuto D, et al. Intermediate filamentous proteins in adult granulosa cell tumors. An immunohistochemical study of 25 cases. Am J Surg Pathol. 1992;16:962–968
  116. Czernobilsky B, Moll R, Levy R, et al. Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of human ovary. Eur J Cell Biol. 1985;37:175–190
  117. McCluggage WG. Ovarian neoplasms composed of small round cells: a review. Adv Anat Pathol. 2004;11:288–296
  118. McCluggage WG, Oliva E, Connolly LE, et al. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcaemic type. Int J Gynecol Pathol. 2004;23:330–336
  119. Carlson JW, Nucci MR, Brodsky J, et al. Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis. Histopathology. 2007;51:305–312
  120. Sumathi VP, Al-Hussaini M, Connolly LE, et al. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody. Int J Gynecol Pathol. 2004;2:241–247
  121. Young RH, Eichhorn JH, Dickersin GR, et al. Ovarian involvement by the intra-abdominal desmoplastic small round cell tumor with divergent differentiation: a report of three cases. Hum Pathol. 1992;23:454–464
  122. Ordonez NG. Desmoplastic small round cell tumor. II. An ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am J Surg Pathol. 1998;122:1314–1327
  123. Barnoud R, Subourin JC, Pasquier D, et al. Immunohistochemical expression of WT1 by desmoplastic small round cell tumor: a comparative study with other small round cell tumors. Am J Surg Pathol. 2000;24:830–836
  124. McCluggage WG. WT-1 immunohistochemical expression in small round blue cell tumours. Histopathology. 2008;52:631–632
  125. Folpe AL, Hill CE, Parham DM, et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing’s sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol. 2000;24:1657–1662
  126. Irving JA, McCluggage WG. Ovarian spindle cell lesions: a review with emphasis on recent developments and differential diagnosis. Adv Anat Pathol. 2007;14:305–319
  127. Staats PA, McCluggage WG, Clement PB, Young RH. Luteinized thecomas associated with sclerosing peritonitis: a clinical, histopathologic and immunohistochemical analysis of 25 cases. Am J Surg Pathol, in press.
  128. Lerwill MF, Sung R, Oliva E, et al. Smooth muscle tumors of the ovary: a clinicopathologic study of 54 cases emphasizing prognostic criteria, histologic variants and differential diagnosis. Am J Surg Pathol. 2004;28:1436–1451
  129. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology. 2001;39:273–278
  130. Oliva E, Young RH, Amin MB, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol. 2002;26:403–412
  131. Nucci MR, O’Connell JT, Huettner PC, et al. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol. 2001;25:455–463
  132. Bhargava R, Shia J, Hummer AJ, et al. Distinction of endometrial stromal sarcomas from ‘hemangiopericytomatous’ tumors using a panel of immunohistochemical stains. Mod Pathol. 2005;18:40–47
  133. Moinfar F, Regitnig P, Tabrizi AD, et al. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms. Virchows Arch. 2004;444:410–414
  134. Reich O, Nogules FF, Regauer S. Gonadotrophin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol. 2005;18:573–576
  135. Orlandi A, Ferlosio A, Ciucci A, et al. Cellular retinol-binding-protein-1 expression in endometrial stromal cells: physiopathological and diagnostic implications. Histopathology. 2004;45:511–517
  136. Irving JS, Lerwill M, Young RH. Gastrointesteinal stromal tumors metastatic to the ovary: a report of five cases. Am J Surg Pathol. 2005;29:920–926
  137. Foster R, Solano S, Mahoney J, et al. Reclassification of a tubal leiomyosarcoma as an eGIST by molecular evaluation of C-KIT. Gynecol Oncol. 2006;101:363–366
  138. Nucci MR, Krausz T, Lifschitz-Mercer B, et al. Angiosarcoma of the ovary: clinicopathologic and immunohistochemical analysis of four cases with a broad morphologic spectrum. Am J Surg Pathol. 1998;22:620–630
  139. Tornos C, Silva EG, Ordonez NG, et al. Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion. A report of 14 cases. Am J Surg Pathol. 1995;19:1343–1353
  140. Roth LM, Talerman A. Recent advances in pathology and classification of ovarian germ cell tumors. Int J Gynecol Pathol. 2006;25:305–320
  141. Ramalingam P, Malpica A, Silva EG, et al. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol. 2004;28:1499–1505
  142. Cheng L, Thomas A, Roth LM, et al. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004;28:1341–1346
  143. Szyfelbein WM, Young RH, Scully RE. Struma ovarii simulating ovarian tumors of other types. A report of 30 cases. Am J Surg Pathol. 1995;19:21–29
  144. Szyfelbein WM, Young RH, Scully RE. Cystic struma ovarii: a frequently unrecognized tumor. A report of 20 cases. Am J Surg Pathol. 1994;18:785–788
  145. Kleinman GM, Young RH, Scully RE. Primary neuroectodermal tumors of the ovary. A report of 25 cases. Am J Surg Pathol. 1993;17:764–778
  146. Palmer PE, Bogojavlensky S, Bhan AK, et al. Prolactinoma in wall of ovarian dermoid cyst with hyperprolactinemia. Obstet Gynecol. 1990;75:540–543
  147. Axiotis CA, Lippes HA, Merino MJ, et al. Corticotroph cell pituitary adenoma within an ovarian teratoma. A new cause of Cushing’s syndrome. Am J Surg Pathol. 1987;11:218–224
  148. Zhao C, Bratthauer GL, Barner R, Vang R. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian Sertoli cell tumor from endometrioid tumors and carcinoid tumor: a study of 160 cases. Am J Surg Pathol. 2007;31:255–266
  149. McCluggage WG, Young RH. Paraganglioma of the ovary: report of three cases of a rare ovarian neoplasm, including two exhibiting inhibin positivity. Am J Surg Pathol. 2006;30:600–605
  150. Phillips VP, McCluggage WG, Young RH. Oxyphilic adenomatoid tumor of the ovary: a case report with discussion of the differential diagnosis of ovarian tumors with vacuoles and related spaces. Int J Gynecol Pathol. 2007;26:16–20
  151. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139–1148
  152. Attanoos RL, Griffin A, Gibbs A. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and bcl-2. Histopathology. 2003;43:231–238
  153. Devouassoux-Shisheboran M, Silver SA, Tavassoli FA. Wolffian adnexal tumor, so-called female adnexal tumor of probable Wolffian origin (FATWO): immunohistochemical evidence in support of a Wolffian origin. Hum Pathol. 1999;30:856–863
  154. Tiltman AJ, Allard U. Female adnexal tumors of probable Wolffian origin: an immunohistochemical study comparing tumours, mesonephric remnants and paramesonephric derivatives. Histopathology. 2001;38:327–342
  155. Ferry JA, Young RH. Malignant lymphoma of the genitourinary tract. Curr Diagn Pathol. 1997;4:145–169
  156. Oliva E, Ferry JA, Young RH, et al. Granulocytic sarcoma of the female genital tract: a clinicopathologic study of 11 cases. Am J Surg Pathol. 1997;21:1156–1165
  157. Lagoo AS, Robboy SJ. Lymphoma of the female genital tract: correct status. Int J Gynecol Pathol. 2006;25:1–21
  158. Matias-Guiu X, Aranda I, Prat J. Immunohistochemical study of sarcoma-like mural nodules in a mucinous cystadenocarcinoma of the ovary. Virchows Arch A Pathol Anat Histopathol. 1991;419:89–92
  159. Hanselaar AGJM, Vooijs GP, Mayall B, et al. Epithelial markers to detect occult microinvasion in serous ovarian tumors. Int J Gynecol Pathol. 1993;12:20–27

PII: S1756-2317(08)00093-5

doi: 10.1016/j.mpdhp.2008.06.008

Diagnostic Histopathology
Volume 14, Issue 8 , Pages 335-351 , August 2008

Article Tools

* Image Usage & Resolution